OptiBiotix Health Stock Price, News & Analysis (LON:OPTI)

GBX 58.80 +1.30 (+2.26 %)
(As of 02/18/2018 04:00 PM ET)
Previous CloseGBX 58.80
Today's RangeGBX 56.14 - GBX 58.80
52-Week RangeGBX 54.30 - GBX 90
Volume141,594 shs
Average Volume231,578 shs
Market Capitalization£48.77 million
P/E Ratio1,960.00
Dividend YieldN/A
BetaN/A

About OptiBiotix Health (LON:OPTI)

OptiBiotix Health logoOptibiotix Health Plc is a life sciences company developing a range of products to modify the human microbiome. The Company's principal activity is research and development into microbiome modulators. It operates in UK segment. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is operated by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology. Its Optiscreen is a screening and optimization technology platform designed to identify microbes within the human microbiome with metabolic pathways, which can interact with human physiological processes. Its OptiBiotic is a platform technology, which generates compounds and screens them for their ability to modulate the human microbiome and its microbial end products. Its platforms are applicable across a range of other human diseases.

Receive OPTI News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolLON:OPTI
CUSIPN/A
Phone+44-20-79338780

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio1960
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.03
Net IncomeN/A
Net Margins4,282.73%
Return on Equity97.34%
Return on Assets89.66%

Miscellaneous

EmployeesN/A
Outstanding Shares78,790,000

OptiBiotix Health (LON:OPTI) Frequently Asked Questions

What is OptiBiotix Health's stock symbol?

OptiBiotix Health trades on the London Stock Exchange (LON) under the ticker symbol "OPTI."

Who are some of OptiBiotix Health's key competitors?

Who are OptiBiotix Health's key executives?

OptiBiotix Health's management team includes the folowing people:

  • David Eric Evans, Co-Chairman of the Board
  • Stephen O'Hara, Chief Executive Officer, Executive Director
  • Christina Wood, Sales and Marketing Director
  • Per Rehne, Commercial Director, Director
  • Luis Gosalbez, Director of Business Development
  • Richard Colin Neil Davidson CBE, Non-Executive Chairman of the Board
  • Gareth Allan Barker, Non-Executive Director
  • Jan Peter Fredrik Wennstrom, Non-Executive Director (Age 58)

How do I buy OptiBiotix Health stock?

Shares of OptiBiotix Health and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is OptiBiotix Health's stock price today?

One share of OptiBiotix Health stock can currently be purchased for approximately GBX 58.80.

How big of a company is OptiBiotix Health?

OptiBiotix Health has a market capitalization of £48.77 million.

How can I contact OptiBiotix Health?

OptiBiotix Health's mailing address is Innovation Centre, Innovation Way, HESLINGTON, YO10 5DG, United Kingdom. The company can be reached via phone at +44-20-79338780.


MarketBeat Community Rating for OptiBiotix Health (OPTI)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  52 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about OptiBiotix Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OptiBiotix Health (LON:OPTI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A

OptiBiotix Health (LON:OPTI) Consensus Price Target History

Price Target History for OptiBiotix Health (LON:OPTI)

OptiBiotix Health (LON:OPTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/23/2018FinnCapReiterated RatingCorporateView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Earnings History for OptiBiotix Health (LON:OPTI)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

OptiBiotix Health (LON:OPTI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for OptiBiotix Health (LON:OPTI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

OptiBiotix Health (LON OPTI) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for OptiBiotix Health (LON:OPTI)

OptiBiotix Health (LON OPTI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2018Neil DavidsonInsiderBuy165,000GBX 60£99,000
(Data available from 1/1/2013 forward)

Headlines

OptiBiotix Health (LON OPTI) News Headlines

Source:
DateHeadline
Optibiotix Health Issues 800,000 Shares Following Warrants Exercise (ALLISS)Optibiotix Health Issues 800,000 Shares Following Warrants Exercise (ALLISS)
www.morningstar.co.uk - February 6 at 8:52 AM
Neil Davidson Acquires 165,000 Shares of OptiBiotix Health PLC (OPTI) StockNeil Davidson Acquires 165,000 Shares of OptiBiotix Health PLC (OPTI) Stock
www.americanbankingnews.com - February 1 at 12:21 PM
OptiBiotix Health Raises GBP28,000 After Warrant Exercise (ALLISS)OptiBiotix Health Raises GBP28,000 After Warrant Exercise (ALLISS)
www.morningstar.co.uk - January 30 at 4:44 PM
OptiBiotix Health (OPTI) Receives "Corporate" Rating from FinnCapOptiBiotix Health (OPTI) Receives "Corporate" Rating from FinnCap
www.americanbankingnews.com - December 25 at 9:26 AM
OptiBiotix Licenses Weight Loss Product SlimBiome To US FirmOptiBiotix Licenses Weight Loss Product SlimBiome To US Firm
www.morningstar.co.uk - December 12 at 10:38 AM
OptiBiotix Health Appoints Neil Davidson Non-Executive ChairmanOptiBiotix Health Appoints Neil Davidson Non-Executive Chairman
www.morningstar.co.uk - December 6 at 4:45 PM
FinnCap Reiterates "Corporate" Rating for OptiBiotix Health plc (OPTI)FinnCap Reiterates "Corporate" Rating for OptiBiotix Health plc (OPTI)
www.americanbankingnews.com - November 23 at 11:20 PM
Should You Buy OptiBiotix Health plc (AIM:OPTI) At This PE Ratio?Should You Buy OptiBiotix Health plc (AIM:OPTI) At This PE Ratio?
finance.yahoo.com - November 21 at 9:01 AM
Is OptiBiotix Health plc’s (AIM:OPTI) PE Ratio A Signal To Buy For Investors?Is OptiBiotix Health plc’s (AIM:OPTI) PE Ratio A Signal To Buy For Investors?
finance.yahoo.com - September 16 at 7:28 AM
Optibiotix Health Plc : Fairly valued, but don’t skip the other factorsOptibiotix Health Plc : Fairly valued, but don’t skip the other factors
finance.yahoo.com - September 14 at 8:50 AM
Optibiotix Health Plc :OPTI-GB: Earnings Analysis: For the six months ended May 31, 2017 : September 12, 2017Optibiotix Health Plc :OPTI-GB: Earnings Analysis: For the six months ended May 31, 2017 : September 12, 2017
finance.yahoo.com - September 12 at 8:14 AM
OptiBiotix Signs LP-LDL Product Development Deal With New Zealand FirmOptiBiotix Signs LP-LDL Product Development Deal With New Zealand Firm
www.morningstar.co.uk - July 17 at 9:11 AM
OptiBiotix Health Secures First Sales Of LP-LDL From German Market - London South East (registration) (blog)OptiBiotix Health Secures First Sales Of LP-LDL From German Market - London South East (registration) (blog)
www.lse.co.uk - April 25 at 8:15 AM
OptiBiotix Health To Float SkinBioTherapeutics On ...OptiBiotix Health To Float SkinBioTherapeutics On ...
www.morningstar.co.uk - March 21 at 11:14 AM
OptiBiotix Awards Exclusive LPLDL Licence Covering Europe To SaccoOptiBiotix Awards Exclusive LPLDL Licence Covering Europe To Sacco
www.morningstar.co.uk - March 8 at 8:44 PM
OptiBiotix To Launch Cholesterol Reducing Products At Trade ShowOptiBiotix To Launch Cholesterol Reducing Products At Trade Show
www.morningstar.co.uk - March 1 at 10:20 AM
OPTI. seeing good b-OPTI. seeing good b-
www.lse.co.uk - January 10 at 7:55 PM
Notice of General Meeting of Warrant Holders - London South East (registration) (blog)Notice of General Meeting of Warrant Holders - London South East (registration) (blog)
www.lse.co.uk - December 23 at 7:12 PM
Joint Product Agreement with multinational - London South East (registration) (blog)Joint Product Agreement with multinational - London South East (registration) (blog)
www.lse.co.uk - December 14 at 12:31 AM

SEC Filings

OptiBiotix Health (LON:OPTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

OptiBiotix Health (LON OPTI) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.